Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non‑Human Primates: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg
GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non‑Human Primates


Regulatory News:



GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies

 
MND : First in Georgia: the Gudauri ski resort operates their new Remote Avalanche Control Systems thanks to MND SAFETY
MND : First in Georgia: the Gudauri ski resort operates their new Remote Avalanche Control Systems thanks to MND SAFETY

MND, n°1 worldwide in avalanche risk prevention and control via its business line MND SAFETY, with its Georgian partner Mountain Resorts Solutions (MRS) have deployed the first ever avalanche risk

 
GROUPE LDLC : 2020-2021 NINE-MONTH REVENUES UP 45.5% TO EUR 542.1M
GROUPE LDLC : 2020-2021 NINE-MONTH REVENUES UP 45.5% TO EUR 542.1M
  • Q3 REVENUES UP 51.3% TO €227.8M (UP 27.1% LIKE FOR LIKE)
  • VERY STRONG GROWTH MOMENTUM IN ALL BUSINESSES
  • 2020-2021 TARGETS REVISED UPWARDS: REVENUES OF AROUND €700M WITH EBITDA CLOSE TO €60M
 
MND : Opening of the new attraction in the heart of the Canton Tower: MND reinvents urban leisure activities
MND : Opening of the new attraction in the heart of the Canton Tower: MND reinvents urban leisure activities

It is in the heart of the famous and vertiginous Canton Tower in China, one of the most spectacular buildings in the world due to its architecture and its hyperboloid structure, 600 meters high

GenSight Biologics Reports Cash Position as of December 31, 2020 and Provides Operational Update: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg
GenSight Biologics Reports Cash Position as of December 31, 2020 and Provides Operational Update


Regulatory News:



GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies

Granite REIT Declares Distribution for January 2021: https://mms.businesswire.com/media/20191217005844/en/763597/5/Granite_REIT_rgb.png.jpg
Granite REIT Declares Distribution for January 2021


Granite Real Estate Investment Trust (“Granite”) (TSX: GRT.UN / NYSE: GRP.U) announced today that its board of trustees has declared a distribution of CAD $0.250 per stapled unit for the month of

GenSight Biologics Announces its 2021 Financial Calendar: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg
GenSight Biologics Announces its 2021 Financial Calendar


Regulatory News:



GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies

GenSight Biologics Announces Publication of Results from LUMEVOQ® RESCUE Pivotal Phase III Trial in AAO journal Ophthalmology®: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg
GenSight Biologics Announces Publication of Results from LUMEVOQ® RESCUE Pivotal Phase III Trial in AAO journal Ophthalmology®


Regulatory News:



GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies

Hitachi Metals Enters Technical Alliance With Teikuro in Surface Treatment Business for Dies in the North American Market: https://mms.businesswire.com/media/20210111005001/en/542622/5/dl_mmc_002.jpg
Hitachi Metals Enters Technical Alliance With Teikuro in Surface Treatment Business for Dies in the North American Market


Hitachi Metals, Ltd. (hereinafter “Hitachi Metals”) is pleased to announce that it has entered into a licensing agreement with Teikuro Inc. (hereinafter “Teikuro”) for the technical provision of

Hitachi Metals Enters Technical Alliance With Teikuro in Surface Treatment Business for Dies in the North American Market: https://mms.businesswire.com/media/20210111005001/en/542622/5/dl_mmc_002.jpg
Hitachi Metals Enters Technical Alliance With Teikuro in Surface Treatment Business for Dies in the North American Market


Hitachi Metals, Ltd. (hereinafter “Hitachi Metals”) is pleased to announce that it has entered into a licensing agreement with Teikuro Inc. (hereinafter “Teikuro”) for the technical provision of

Hitachi Metals Enters Technical Alliance With Teikuro in Surface Treatment Business for Dies in the North American Market: https://mms.businesswire.com/media/20210111005001/en/542622/5/dl_mmc_002.jpg
Hitachi Metals Enters Technical Alliance With Teikuro in Surface Treatment Business for Dies in the North American Market


Hitachi Metals, Ltd. (hereinafter “Hitachi Metals”) is pleased to announce that it has entered into a licensing agreement with Teikuro Inc. (hereinafter “Teikuro”) for the technical provision of

Hitachi Metals Enters Technical Alliance With Teikuro in Surface Treatment Business for Dies in the North American Market: https://mms.businesswire.com/media/20210111005001/en/542622/5/dl_mmc_002.jpg
Hitachi Metals Enters Technical Alliance With Teikuro in Surface Treatment Business for Dies in the North American Market


Hitachi Metals, Ltd. (hereinafter “Hitachi Metals”) is pleased to announce that it has entered into a licensing agreement with Teikuro Inc. (hereinafter “Teikuro”) for the technical provision of

Lysogene Receives MHRA and Research Ethics Committee Approvals to Initiate the Gene Therapy Clinical Trial in the UK with LYS-GM101 for the Treatment of GM1 Gangliosidosis
Lysogene Receives MHRA and Research Ethics Committee Approvals to Initiate the Gene Therapy Clinical Trial in the UK with LYS-GM101 for the Treatment of GM1 Gangliosidosis


Regulatory News:



Lysogene (Paris:LYS) (FR0013233475 – LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announces that it has received MHRA and

EOS Imaging Reports Full-Year 2020 Revenue up +19% Year-on-year
EOS Imaging Reports Full-Year 2020 Revenue up +19% Year-on-year


Regulatory News:



EOS imaging (Euronext, FR0011191766 - EOSI - PEA-PME eligible) (Paris:EOSI), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and

CI Financial Completes Acquisition of Four RIA Firms, Capping a Year of Rapid Growth in U.S. Wealth Management: https://mms.businesswire.com/media/20201105006022/en/836403/5/CI-F_-_RGB_E.jpg
CI Financial Completes Acquisition of Four RIA Firms, Capping a Year of Rapid Growth in U.S. Wealth Management


CI Financial Corp. (“CI”) (TSX: CIX; NYSE: CIXX), a diversified global asset and wealth management company, today announced it has completed the acquisition of four U.S. registered investment

Everbridge Surpasses 5 Billion Communications in 2020 From its Critical Event Management (CEM) Platform, Supporting Business, Healthcare, and Government Organizations Around the World
Everbridge Surpasses 5 Billion Communications in 2020 From its Critical Event Management (CEM) Platform, Supporting Business, Healthcare, and Government Organizations Around the World


Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM), today announced a new milestone in its support of business, healthcare and government organizations during an

Granite REIT Notice of Conference Call for Fourth Quarter and Year-End 2020 Results: https://mms.businesswire.com/media/20191217005844/en/763597/5/Granite_REIT_rgb.png.jpg
Granite REIT Notice of Conference Call for Fourth Quarter and Year-End 2020 Results


Granite Real Estate Investment Trust (“Granite”) (TSX: GRT.UN / NYSE: GRP.U) expects to announce its financial results for the fourth quarter and year-ended December 31, 2020 after the close of

Lysogene Reports Positive Biomarker Data With LYS-SAF302
Lysogene Reports Positive Biomarker Data With LYS-SAF302


Regulatory News:



Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today reports positive biomarker data from the

EOS imaging Announces Its Financial Agenda For 2021
EOS imaging Announces Its Financial Agenda For 2021


Regulatory News:



EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and

Granite REIT Issues Notice of Redemption of 3.788% Senior Debentures Due 2021: https://mms.businesswire.com/media/20191217005844/en/763597/5/Granite_REIT_rgb.png.jpg
Granite REIT Issues Notice of Redemption of 3.788% Senior Debentures Due 2021


Granite Real Estate Investment Trust (“Granite” or the “REIT”) (TSX: GRT.UN / NYSE: GRP.U) announced today that its wholly owned subsidiary Granite REIT Holdings Limited Partnership (“Granite LP”)

Granite REIT Completes Offering of C$500 Million 2.378% Senior Debentures Due 2030: https://mms.businesswire.com/media/20191217005844/en/763597/5/Granite_REIT_rgb.png.jpg
Granite REIT Completes Offering of C$500 Million 2.378% Senior Debentures Due 2030


Granite Real Estate Investment Trust (“Granite” or the “REIT”) (TSX: GRT.UN / NYSE: GRP.U) announced today that its wholly owned subsidiary Granite REIT Holdings Limited Partnership (“Granite LP”)

CI Financial Announces Early Redemption of Debentures due November 2021: https://mms.businesswire.com/media/20201105006022/en/836403/5/CI-F_-_RGB_E.jpg
CI Financial Announces Early Redemption of Debentures due November 2021


CI Financial Corp. (“CI”) (TSX: CIX; NYSE: CIXX) today announced its intention to redeem all of the outstanding $200 million principal amount of 2.775% debentures due November 25, 2021 (“2021

Lysogene Announces a Change in the Organization of KGA, Minority Shareholder of Lysogene
Lysogene Announces a Change in the Organization of KGA, Minority Shareholder of Lysogene


Regulatory News:



Lysogene (Paris:LYS) (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces a change in the governance and

Granite REIT Declares Distribution for December 2020: https://mms.businesswire.com/media/20191217005844/en/763597/5/Granite_REIT_rgb.png.jpg
Granite REIT Declares Distribution for December 2020


Granite Real Estate Investment Trust (“Granite”) (TSX: GRT.UN / NYSE: GRP.U) announced today that its board of trustees has declared a distribution of CAD $0.250 per stapled unit for the month of

 
GECI INTERNATIONAL : 2020-21 FIRST-HALF EARNINGS
GECI INTERNATIONAL : 2020-21 FIRST-HALF EARNINGS

At the Board meeting on December 17, 2020, the Directors reviewed and approved the 2020-21 half-year financial statements for the period ended September 30, 2020.

€m 2020-21 (6 months)